Table 1.

Clinical Characteristics

	Total N (%)	Measured GFR (mL/min) Mean (SD)	Estimated GFR (mL/min) Mean (SD)
			CKD-EPI	MDRD Study	Cockcroft-Gault
All patientsa	200 (100)	97 ± 31	89 ± 28	83 ± 27	89 ± 30
(mL/min per 1.732)	200 (100)	87 ± 26	80 ± 24	75 ± 23	80 ± 23
Age group, years
≤50	132 (66)	103 ± 31	95 ± 27	88 ± 26	96 ± 29
>50	68 (34)	84 ± 28	77 ± 27	74 ± 26	76 ± 29
Sex
Women	55 (28)	85 ± 30	79 ± 26	73 ± 23	85 ± 34
Men	145 (73)	101 ± 31	93 ± 28	87 ± 27	91 ± 29
Race
African Americans	104 (52)	97 ± 34	91 ± 31	86 ± 29	87 ± 32
White or other	96 (48)	96 ± 28	87 ± 25	80 ± 24	92 ± 29
BMI group, kg/m2
<22	35 (18)	83 ± 29	82 ± 28	77 ± 28	70 ± 23
22-30	129 (65)	97 ± 31	90 ± 28	84 ± 26	89 ± 27
>30	36 (18)	106 ± 33	92 ± 30	86 ± 28	109 ± 36
Hypertension b	60 (31)	96 ± 34	85 ± 27	80 ± 26	86 ± 28
Diabetes Mellitus	16 (8)	85 ± 26	81 ± 29	76 ± 26	80 ± 29
Hepatitis B	22 (11)	85 ± 25	80 ± 23	75 ± 21	81 ± 25
Hepatitis C	51 (26)	87 ± 27	86 ± 29	80 ± 27	84 ± 32
CD4 count group, cells/ulb
<350	47 (25)	95 ± 30	88 ± 29	82 ± 27	87 ± 32
≥350	144 (75)	97 ± 32	90 ± 28	84 ± 27	91 ± 30
Viral load group, copies/mb
Undetected	111 (61)	93 ± 32	86 ± 29	80 ± 27	86 ± 30
<1000	57 (31)	106 ± 30	97 ± 26	90 ± 25	100 ± 30
≥1000	14 (8)	94 ± 32	90 ± 32	86 ± 29	80 ± 28
Tenofovir use/exposure
Yes	125 (63)	97 ± 31	89 ± 28	83 ± 26	91 ± 31
No	75 (38)	96 ± 33	89 ± 30	83 ± 29	87 ± 29
Source of HIV Transmission
Injection	24 (12)	93 ± 27	92 ± 25	86 ± 23	88 ± 26
Male-to-male	75 (38)	97 ± 30	92 ± 30	86 ± 29	89 ± 29
Heterosexual	51 (26)	102 ± 32	89 ± 29	83 ± 27	96 ± 35
Other	50 (25)	92 ± 34	84 ± 27	78 ± 25	83 ± 28

Note: Values are mean ± standard deviation or number (percentage).

^ap<0.001 for comparison of each kidney function estimate to measured GFR

^b5 patients had missing data for hypertension; 1 patient for diabetes mellitus, 9 patients for CD4 count and 18 patients for viral load

Tenofovir (Viread®)